Finding new treatments to help people quit smoking
Discovery and development of GPR3 agonists for nicotine cessation
['FUNDING_R01'] · RESEARCH TRIANGLE INSTITUTE · NIH-10934370
This study is looking at how a certain brain receptor called GPR3 influences the way nicotine affects us, with the goal of finding new treatments to help people quit smoking.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH TRIANGLE INSTITUTE (nih funded) |
| Locations | 1 site (RESEARCH TRIANGLE PARK, UNITED STATES) |
| Trial ID | NIH-10934370 on ClinicalTrials.gov |
What this research studies
This research investigates the role of a specific receptor, GPR3, in how nicotine affects the brain, particularly in terms of addiction and aversion. The team will screen a large number of compounds to identify potential GPR3 agonists that could help in nicotine cessation. By understanding how these compounds work, the researchers aim to develop new therapies that could improve the success rates of quitting smoking. The project combines advanced screening techniques and biological assays to find effective solutions for tobacco addiction.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are struggling with nicotine addiction and are looking for new ways to quit smoking.
Not a fit: Patients who are not nicotine users or those who have successfully quit smoking may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for individuals trying to quit smoking, potentially increasing cessation success rates.
How similar studies have performed: While the approach of targeting GPR3 for nicotine cessation is relatively novel, similar research has shown promise in identifying new therapeutic targets for addiction treatment.
Where this research is happening
RESEARCH TRIANGLE PARK, UNITED STATES
- RESEARCH TRIANGLE INSTITUTE — RESEARCH TRIANGLE PARK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GAY, ELAINE ARRINGTON — RESEARCH TRIANGLE INSTITUTE
- Study coordinator: GAY, ELAINE ARRINGTON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.